130 related articles for article (PubMed ID: 26174899)
1. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012.
Robert P; Hotchko M
Transfusion; 2015 Jul; 55 Suppl 2():S6-12. PubMed ID: 26174899
[No Abstract] [Full Text] [Related]
2. Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD
Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597
[TBL] [Abstract][Full Text] [Related]
3. IgG replacement therapy, no size fits all.
Bonilla FA
Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
[No Abstract] [Full Text] [Related]
4. Subcutaneous IgG in neurologic diseases.
Berger M
Immunotherapy; 2014; 6(1):71-83. PubMed ID: 24341886
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of intravenous immunoglobulin therapy.
Ryan ME; Webster ML; Statler JD
Clin Pediatr (Phila); 1996 Jan; 35(1):23-31. PubMed ID: 8825847
[No Abstract] [Full Text] [Related]
6. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants.
Meckley LM; Wu Y; Tzivelekis S; Gandhi V; Gladiator A
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):568-574.e1. PubMed ID: 34224864
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenously administered immune globulin in newborn infants: prophylaxis, treatment, both, or neither?
Berger M
J Pediatr; 1991 Apr; 118(4 Pt 1):557-9. PubMed ID: 1901082
[No Abstract] [Full Text] [Related]
8. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
[TBL] [Abstract][Full Text] [Related]
9. The immune system. Part II, Intravenous administration of immune globulin.
Frey AM
J Intraven Nurs; 1991; 14(6):396-405. PubMed ID: 1748921
[TBL] [Abstract][Full Text] [Related]
10. Summary of the ASHP therapeutic guidelines for intravenous immune globulin. ASHP Commission on Therapeutics.
Am J Hosp Pharm; 1992 Mar; 49(3):652-4. PubMed ID: 1598949
[No Abstract] [Full Text] [Related]
11. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates.
Baker CJ; Melish ME; Hall RT; Casto DT; Vasan U; Givner LB
N Engl J Med; 1992 Jul; 327(4):213-9. PubMed ID: 1614462
[TBL] [Abstract][Full Text] [Related]
12. Safety of L-proline as a stabilizer for immunoglobulin products.
Hagan JB; Wasserman RL; Baggish JS; Spycher MO; Berger M; Shashi V; Lohrmann E; Sullivan KE
Expert Rev Clin Immunol; 2012 Feb; 8(2):169-78. PubMed ID: 22288455
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immune human serum globulin.
Noerr B
Neonatal Netw; 1990 Apr; 8(5):81-3. PubMed ID: 2319996
[No Abstract] [Full Text] [Related]
14. Differences between IGIV products: impact on clinical outcome.
Gelfand EW
Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
[TBL] [Abstract][Full Text] [Related]
15. High-dose intravenous gamma globulin therapy for immune thrombocytopenia.
Reding D; Amare M
Wis Med J; 1988 Feb; 87(2):11-3. PubMed ID: 3126604
[No Abstract] [Full Text] [Related]
16. The assessment and management of primary antibody deficiency.
Empson M; Sinclair J; O'Donnell J; Ameratunga R; Fitzharris P; Steele R;
N Z Med J; 2004 Jun; 117(1195):U914. PubMed ID: 15282626
[No Abstract] [Full Text] [Related]
17. The nurse's role in administration of intravenous immunoglobulin therapy.
Kirmse J
Home Healthc Nurse; 2009 Feb; 27(2):104-11; quiz 112-3. PubMed ID: 19212223
[TBL] [Abstract][Full Text] [Related]
18. Complications of intravenous immune globulin treatment in neurologic disease.
Achiron A
Neurology; 1997 Sep; 49(3):899-900. PubMed ID: 9305372
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
20. Nursing guidelines for administration of immunoglobulin replacement therapy.
Younger ME; Aro L; Blouin W; Duff C; Epland KB; Murphy E; Sedlak D;
J Infus Nurs; 2013; 36(1):58-68. PubMed ID: 23271153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
